Chembio Diagnostics, Inc. (NASDAQ:CEMI) was the target of some unusual options trading activity on Wednesday. Investors acquired 12,922 call options on the company. This represents an increase of 1,101% compared to the average daily volume of 1,076 call options.
Shares of CEMI traded up $3.43 during trading on Wednesday, reaching $5.49. 3,098,759 shares of the company traded hands, compared to its average volume of 455,264. Chembio Diagnostics has a twelve month low of $2.06 and a twelve month high of $8.75. The firm has a market cap of $111.17 million, a PE ratio of -3.13 and a beta of 1.85. The business’s 50-day moving average is $3.00. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.86 and a current ratio of 3.42.
Chembio Diagnostics (NASDAQ:CEMI) last announced its quarterly earnings results on Thursday, May 6th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. The business had revenue of $8.72 million during the quarter. Chembio Diagnostics had a negative net margin of 72.88% and a negative return on equity of 79.63%. Sell-side analysts predict that Chembio Diagnostics will post -1.13 EPS for the current fiscal year.
Separately, Zacks Investment Research upgraded shares of Chembio Diagnostics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 7th.
Chembio Diagnostics Company Profile
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases.
Featured Story: Bear Market – How and Why They Occur
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.